Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl H June

Showing results (141-150 of 460) with videos related to

Pageof 46
Sort By:
Current Surgery Reports|April 17, 2018
Immunotherapy for Breast Cancer: Current and Future StrategiesAustin D Williams, Kyle K Payne, Avery D Posey, et al.
JCI Insight|June 17, 2020
A rational mouse model to detect on-target, off-tumor CAR T cell toxicityMauro Castellarin, Caroline Sands, Tong Da, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 23, 2010
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3: 87-98Lawrence H Boise, Andy J Minn, Patricia J Noel, et al.
Clinical Immunology (Orlando, Fla.)|March 14, 2002
Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patientsChristina S Chu, Edward Y Woo, Alanna J Toll, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 7, 2002
Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferationBirgit Kovacs, Marcela V Maus, James L Riley, et al.
Blood|March 20, 2004
In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR culturesWayne R Godfrey, Ying G Ge, Darrin J Spoden, et al.
Journal of Translational Medicine|August 11, 2011
Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytesQunrui Ye, Maria Loisiou, Bruce L Levine, et al.
Cancer Research|February 2, 2017
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor EfficacyCarlos Alberto Fajardo, Sonia Guedan, Luis Alfonso Rojas, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 23, 2003
Development of novel substrates for tumor immunotherapyWaleed S W Shalaby, Heidi Yeh, Edward Woo, et al.
Nature Communications|May 10, 2024
The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretionUgur Uslu, Lijun Sun, Sofia Castelli, et al.
Pageof 46

Showing results (141-150 of 460) with videos related to

Sort By:
Pageof 46
Current Surgery Reports|April 17, 2018
Immunotherapy for Breast Cancer: Current and Future StrategiesAustin D Williams, Kyle K Payne, Avery D Posey, et al.
JCI Insight|June 17, 2020
A rational mouse model to detect on-target, off-tumor CAR T cell toxicityMauro Castellarin, Caroline Sands, Tong Da, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 23, 2010
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3: 87-98Lawrence H Boise, Andy J Minn, Patricia J Noel, et al.
Clinical Immunology (Orlando, Fla.)|March 14, 2002
Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patientsChristina S Chu, Edward Y Woo, Alanna J Toll, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 7, 2002
Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferationBirgit Kovacs, Marcela V Maus, James L Riley, et al.
Blood|March 20, 2004
In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR culturesWayne R Godfrey, Ying G Ge, Darrin J Spoden, et al.
Journal of Translational Medicine|August 11, 2011
Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytesQunrui Ye, Maria Loisiou, Bruce L Levine, et al.
Cancer Research|February 2, 2017
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor EfficacyCarlos Alberto Fajardo, Sonia Guedan, Luis Alfonso Rojas, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 23, 2003
Development of novel substrates for tumor immunotherapyWaleed S W Shalaby, Heidi Yeh, Edward Woo, et al.
Nature Communications|May 10, 2024
The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretionUgur Uslu, Lijun Sun, Sofia Castelli, et al.
Pageof 46